Kanada - Kiingereza - Health Canada

mylan pharmaceuticals ulc - clozapine - suspension - 50mg - clozapine 50mg - atypical antipsychotics

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 200mg;   - tablet - 200 mg - active: clozapine 200mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

britannia pharmaceuticals ltd - clozapine - oral tablet - 200mg

Kanada - Kiingereza - Health Canada

auro pharma inc - clozapine - tablet - 25mg - clozapine 25mg - atypical antipsychotics

Kanada - Kiingereza - Health Canada

auro pharma inc - clozapine - tablet - 50mg - clozapine 50mg - atypical antipsychotics

Kanada - Kiingereza - Health Canada

auro pharma inc - clozapine - tablet - 100mg - clozapine 100mg - atypical antipsychotics

Marekani - Kiingereza - NLM (National Library of Medicine)

heartwood pharma - clozapine (unii: j60ar2ikic) (clozapine - unii:j60ar2ikic) - clozapine tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. because of the risks of severe neutropenia and of seizure associated with its use, clozapine tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see warnings and precautions (5.1, 5.5)] . the effectiveness of clozapine tablets in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine and chlorpromazine in patients who had failed other antipsychotics [see clinical studies (14.1)] . clozapine tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. suicidal behavior refers to actions by a patient that put him/herself at

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).